NorthWest Biotherapeutics Inc (NWBO)

[Umibe5690]

Doc Logic

The lack of formal FDA guidance and delay is a real and foreseeable issue. Regulators often times move slow as molasses.

I am certain that NWBO’s regulatory counsel has made NWBO management well aware of this and a possible issue wrt a US journal willing to publish upon condition and when formal guidelines issue from the FDA wrt ECAs.

Accordingly, in an abundance of caution, I believe that in order to avoid this possible issue and hold up, NWBO in collaboration with the authors and strong support from Dr Ashkans opted to go with a UK journal. JMHO.